How do we keep blood cancer research moving forward? Three talks at #SOHO2026 explore alternative approaches to funding blood cancer science, from foundations to patient advocacy groups to academic clinical trial partnerships.

Read more here: sohoinsider.com/meetings-con...

Read the new Clinical Hemato-Oncology article collection showcasing Blood Cancer Discovery content on clinical hemato-oncology research and practice, encompassing biology-informed prognostication, new therapies, clinical trials, and post-approval real-life outcomes. buff.ly/LqRwkla #SOHO2026

CELMoDs in multiple myeloma: a decade of progress. Dr. Ajay Nooka reviews the clinical development of iberdomide and mezigdomide for #SOHO2026

Read more here: sohoinsider.com/news/celmods...

Phase 1 data show that dibotatug produced a 60% overall response rate with a favorable safety profile in large granular lymphocytic leukemia. @societyofhemonc.bsky.social #SOHO2026 #leusm #hematology

www.onclive.com/view/dibotat...

Saturday, September 12, 10:25–10:35 AM Dr. Elias Jabbour previews Next Questions: Acute Lymphoblastic Leukemia at #SOHO2026, covering CAR T-cell therapy's future role, CNS relapse, T-cell ALL, and whether transplant is still needed after CAR T.

Read more: sohoinsider.com/meetings-con...

The ASC4FIRST trial continued to show higher molecular response rates and better tolerability with asciminib than with standard TKIs in Ph-positive CML. @societyofhemonc.bsky.social #SOHO2026 #leusm #hematology

www.onclive.com/view/ascimin...

Looking for more data on rusfertide in polycythemia vera following the FDA's August approval? Dive into a subgroup analysis of the VERIFY trial presented at #SOHO2026 #mpnsm #oncology www.onclive.com/view/rusfert...

New research presented at the @societyofhemonc.bsky.social 2026 Annual Meeting showed promising results for a specific group of patients with AL amyloidosis. #SOHO2026

Read the full article here: https://bit.ly/4ikR2fF

Saturday, September 12, 12:15–12:25 PM Dr. Guillermo García-Manero previews Next Questions: Myelodysplastic Syndromes at #SOHO2026, sharing what's next for treating both higher-risk and lower-risk MDS.

Read more: sohoinsider.com/news/definin...

More from #SOHO2026! Frontline 2nd-generation TKIs (dasatinib/nilotinib) show significantly more durable disease control than imatinib in Ph+ ALL

High baseline disease burden (hemoglobin < 8 g/dL, LDH ≥ 691 U/L, higher BCR::ABL1) independently predicted worse outcomes.

More: https://bit.ly/46kVhAB

📈MPN expert, Andrew Kuykendall, MD, of Moffitt Cancer Center, ranked these headlining novel treatments in MPNs at #SOHO2026.

‼️Visit our site for more: www.onclive.com/conference/s...

@societyofhemonc.bsky.social #mpnsm #oncology #hematology #cancer

Read the new Clinical Hemato-Oncology article collection showcasing Blood Cancer Discovery content on clinical hemato-oncology research and practice, encompassing biology-informed prognostication, new therapies, clinical trials, and post-approval real-life outcomes. buff.ly/LqRwkla #SOHO2026

WATCH 👀: Naseema Gangat, MBBS of @mayocliniccancer.bsky.social reviews cohort-specific hematologic response rates and safety findings for selcodebart in myelofibrosis from RALLY-MF.

See the whole video here ➡️: onclive.com/view/dr-gang...

#mpnsm #oncology #SOHO2026 @societyofhemonc.bsky.social

Time-limited pirtobrutinib plus venetoclax and obinutuzumab produced high rates of U-MRD in CLL/SLL. #leusm #hematology

See our site for the full story from PIVOT-CLL, as presented by
@nitinjainmd.bsky.social at #SOHO2026! @societyofhemonc.bsky.social

www.onclive.com/view/time-li...

Although anselamimab missed the primary end point in the overall population, the agent plus anti-PCD improved all-cause mortality and CV-related hospitalization vs placebo in patients with newly diagnosed kappa AL amyloidosis #oncology

Dive into the #SOHO2026 data: www.onclive.com/view/anselam...

Good morning from #SOHO2026! Come by and take a picture at our photobooth we'd love to see you there.

Thank you to Astellas US for their support!

Friday, 9/11, 4:35–6:12 pm Dr. Kami Maddocks previews the MCL session at #SOHO2026. Covering BTK inhibition, transplant strategies, novel treatments in the pipeline and more.

Read more: sohoinsider.com/news/preview...

🚨 New research from #SOHO2026 highlights long-term immune dysfunction in survivors of childhood hematologic malignancies (mostly B-ALL), years after completing therapy.

Source: @societyofhemonc.bsky.social #SOHO26

More here: https://bit.ly/4dv14r4

Updated SUNMO trial data presented at #SOHO2026 shows Mosun-Pola outperforms standard of care (R-GemOx) in transplant-ineligible R/R LBCL! 🔬

🔹Median PFS: 11.6 vs 3.8 months (HR: 0.41)
🔹ORR: 70.3% vs 40.0%
🔹CR: 51.4% vs 24.3%

Link to the story: https://bit.ly/3SXmBBW

#SOHO26

📈 2-year data from the Phase 3 SURPASS-ET trial presented at #SOHO2026 shows continuous ropeginterferon alfa-2b (ropeg) delivers durable hematologic & molecular benefits for high-risk essential thrombocythemia!

More details: https://bit.ly/3TodPwU

#SOHO26 #Thrombocythemia